MX354846B - Metodos para tratar gota en sub-poblaciones de pacientes. - Google Patents
Metodos para tratar gota en sub-poblaciones de pacientes.Info
- Publication number
- MX354846B MX354846B MX2014005399A MX2014005399A MX354846B MX 354846 B MX354846 B MX 354846B MX 2014005399 A MX2014005399 A MX 2014005399A MX 2014005399 A MX2014005399 A MX 2014005399A MX 354846 B MX354846 B MX 354846B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- treating gout
- patient subpopulations
- subject
- subpopulations
- Prior art date
Links
- 201000005569 Gout Diseases 0.000 title 1
- 206010062237 Renal impairment Diseases 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 231100000857 poor renal function Toxicity 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 229940116269 uric acid Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2011/059425 WO2013066352A1 (en) | 2011-11-04 | 2011-11-04 | Methods for treating gout in patient subpopulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014005399A MX2014005399A (es) | 2015-04-08 |
| MX354846B true MX354846B (es) | 2018-03-22 |
Family
ID=48192536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014005399A MX354846B (es) | 2011-11-04 | 2011-11-04 | Metodos para tratar gota en sub-poblaciones de pacientes. |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP2775835A4 (enExample) |
| JP (1) | JP6047172B2 (enExample) |
| KR (1) | KR101848122B1 (enExample) |
| CN (1) | CN104066323A (enExample) |
| AU (1) | AU2011380509B2 (enExample) |
| BR (1) | BR112014010693A2 (enExample) |
| CA (1) | CA2859689C (enExample) |
| CL (1) | CL2014001156A1 (enExample) |
| IL (1) | IL232385A (enExample) |
| MX (1) | MX354846B (enExample) |
| NZ (1) | NZ624714A (enExample) |
| SG (1) | SG11201402027PA (enExample) |
| WO (1) | WO2013066352A1 (enExample) |
| ZA (1) | ZA201403574B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201406495UA (en) * | 2012-04-13 | 2014-11-27 | Cymabay Therapeutics Inc | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent |
| CN106036135A (zh) * | 2014-07-25 | 2016-10-26 | 许伟琦 | 一种防止结石、快速排结石的药物、组合物、兽药 |
| CN105920022A (zh) * | 2016-05-12 | 2016-09-07 | 成都易创思生物科技有限公司 | 一种抗痛风药物复方制剂 |
| US11446317B2 (en) * | 2017-10-26 | 2022-09-20 | Otsuka Pharmaceutical Co., Ltd. | Inositol phosphate-containing composition |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4250191A (en) * | 1978-11-30 | 1981-02-10 | Edwards K David | Preventing renal failure |
| US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| BRPI0819847B1 (pt) * | 2007-11-27 | 2022-01-11 | Ardea Biosciences, Inc | Compostos e composições |
-
2011
- 2011-11-04 NZ NZ624714A patent/NZ624714A/en not_active IP Right Cessation
- 2011-11-04 JP JP2014541012A patent/JP6047172B2/ja not_active Expired - Fee Related
- 2011-11-04 WO PCT/US2011/059425 patent/WO2013066352A1/en not_active Ceased
- 2011-11-04 SG SG11201402027PA patent/SG11201402027PA/en unknown
- 2011-11-04 BR BR112014010693-2A patent/BR112014010693A2/pt not_active IP Right Cessation
- 2011-11-04 KR KR1020147015209A patent/KR101848122B1/ko not_active Expired - Fee Related
- 2011-11-04 AU AU2011380509A patent/AU2011380509B2/en not_active Ceased
- 2011-11-04 CN CN201180076189.7A patent/CN104066323A/zh active Pending
- 2011-11-04 MX MX2014005399A patent/MX354846B/es active IP Right Grant
- 2011-11-04 CA CA2859689A patent/CA2859689C/en not_active Expired - Fee Related
- 2011-11-04 EP EP11875027.2A patent/EP2775835A4/en not_active Withdrawn
-
2014
- 2014-04-30 IL IL232385A patent/IL232385A/en active IP Right Grant
- 2014-05-02 CL CL2014001156A patent/CL2014001156A1/es unknown
- 2014-05-16 ZA ZA2014/03574A patent/ZA201403574B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011380509B2 (en) | 2016-05-19 |
| NZ624714A (en) | 2016-01-29 |
| KR101848122B1 (ko) | 2018-04-11 |
| CL2014001156A1 (es) | 2015-01-16 |
| IL232385A0 (en) | 2014-06-30 |
| BR112014010693A2 (pt) | 2020-11-10 |
| WO2013066352A1 (en) | 2013-05-10 |
| MX2014005399A (es) | 2015-04-08 |
| SG11201402027PA (en) | 2014-09-26 |
| CA2859689C (en) | 2018-05-22 |
| CA2859689A1 (en) | 2013-05-10 |
| EP2775835A1 (en) | 2014-09-17 |
| KR20140123927A (ko) | 2014-10-23 |
| EP2775835A4 (en) | 2015-07-29 |
| JP6047172B2 (ja) | 2016-12-21 |
| IL232385A (en) | 2017-10-31 |
| CN104066323A (zh) | 2014-09-24 |
| ZA201403574B (en) | 2015-11-25 |
| JP2014532759A (ja) | 2014-12-08 |
| AU2011380509A1 (en) | 2014-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2012000152A1 (en) | Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes | |
| EA201490493A1 (ru) | Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы | |
| TN2012000578A1 (en) | Tetrahydro-pyrido-pyrimidine derivatives | |
| PH12013501718A1 (en) | Production method of optically active dihydrobenzofuran derivative | |
| PH12013502144A1 (en) | Multiple myeloma treatment | |
| NZ601805A (en) | Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same | |
| GEP20156318B (en) | Heteroaryl derivatives as alpha7 nachr modulators | |
| BR112013005810A2 (pt) | métodos para reduzir a concentração de lactato no sangue | |
| UA110128C2 (uk) | Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди | |
| GEP20166448B (en) | Ophthalmic solution containing diquafosol, method for producing same, and method for preventing formation of insoluble precipitate | |
| MX2014004920A (es) | Nuevos derivados de pirazina. | |
| AU2011208681A8 (en) | Aqueous solution comprising 3 - quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease | |
| PH12014500990A1 (en) | Methods for treating gout flares | |
| NZ711343A (en) | Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation | |
| FR2980708B1 (fr) | Composition comprenant un gallotannin | |
| MX2014005399A (es) | Metodos para tratar gota en sub-poblaciones de pacientes. | |
| GB201107985D0 (en) | Process | |
| MX2013013417A (es) | Composicion limpiadora para tela que comprende agente tonalizador. | |
| MY172619A (en) | Method for refining quinolinic acid | |
| NZ715554A (en) | Method of treating hypertrophic cardiomyopathy | |
| WO2013090319A3 (en) | Treatment of type i and type ii diabetes | |
| HUE036037T2 (hu) | (3S,3S')4,4'-Diszulfándiil-bisz(3-aminobután-1-szulfonsav), azaz ABSD, L-lizinnel képezett kristályos alakja | |
| WO2011097027A3 (en) | Methods for treating or inhibiting infection by clostridium difficile | |
| MX2012003290A (es) | Composicion para reducir el nivel de acido urico en la sangre. | |
| MX2013006066A (es) | Inhibidor de quinasa janus 2 (jak2) para el tratamiento de lupus. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |